These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35861943)

  • 1. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
    Ito T; Takashima A; Yamazaki K; Yukami H; Uetake H; Tsuda M; Suto T; Moriwaki T; Sugimoto N; Ojima H; Takii Y; Yasui H; Esaki T; Tsuji A; Goto M; Saruta M; Otsu S; Shinozaki K; Fujiwara T; Tamura T; Baba E; Shiozawa M; Denda T; Ueno H; Nagashima K; Shimada Y
    Int J Clin Oncol; 2022 Sep; 27(9):1450-1458. PubMed ID: 35861943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
    Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
    Rossini D; Boccaccino A; Carullo M; Antoniotti C; Dima G; Ciracì P; Marmorino F; Moretto R; Masi G; Cremolini C
    Eur J Cancer; 2023 May; 184():106-116. PubMed ID: 36913832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Watanabe J; Muro K; Shitara K; Yamazaki K; Shiozawa M; Ohori H; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Hihara M; Soeda J; Misumi T; Yamamoto K; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    JAMA; 2023 Apr; 329(15):1271-1282. PubMed ID: 37071094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
    Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
    Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.
    Wang ZX; Wu HX; He MM; Wang YN; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
    J Natl Compr Canc Netw; 2019 Jul; 17(7):805-811. PubMed ID: 31319395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour location and efficacy of first-line EGFR inhibitors in
    Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
    ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
    Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
    Ann Oncol; 2017 Aug; 28(8):1862-1868. PubMed ID: 28449055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
    Holch JW; Held S; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; von Einem JC; Michl M; Heinemann V
    Ann Oncol; 2020 Jan; 31(1):72-78. PubMed ID: 31912799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G).
    Izawa N; Shitara K; Yonesaka K; Yamanaka T; Yoshino T; Sunakawa Y; Masuishi T; Denda T; Yamazaki K; Moriwaki T; Okuda H; Kondoh C; Nishina T; Makiyama A; Baba H; Yamaguchi H; Nakamura M; Hyodo I; Muro K; Nakajima TE
    Target Oncol; 2020 Oct; 15(5):623-633. PubMed ID: 32960408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
    Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
    Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
    Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
    JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.
    Tejpar S; Stintzing S; Ciardiello F; Tabernero J; Van Cutsem E; Beier F; Esser R; Lenz HJ; Heinemann V
    JAMA Oncol; 2017 Feb; 3(2):194-201. PubMed ID: 27722750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary tumor location and survival in colorectal cancer: A retrospective cohort study.
    Aggarwal H; Sheffield KM; Li L; Lenis D; Sorg R; Barzi A; Miksad R
    World J Gastrointest Oncol; 2020 Apr; 12(4):405-423. PubMed ID: 32368319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
    Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
    Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.
    Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
    Clin Colorectal Cancer; 2018 Sep; 17(3):170-178.e3. PubMed ID: 29627309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
    Parisi A; Porzio G; Cannita K; Venditti O; Avallone A; Filippi R; Salvatore L; Tortora G; Ribelli M; Nigro O; Gelsomino F; Spallanzani A; Zurlo V; Leo S; Dell'Aquila E; Claudia F; Lombardi P; Keränen SR; Aimar G; Depetris I; Giampieri R; Morelli C; De Tursi M; Tinari N; Di Pietro FR; De Galitiis F; Zanaletti N; Troiani T; Vitale P; Garajova I; Ghidini M; Spinelli GP; Zoratto F; Roberto M; Ierino D; Petrillo A; D'Orazio C; Ficorella C; Cortellini A
    Clin Colorectal Cancer; 2021 Dec; 20(4):318-325. PubMed ID: 34380594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.